Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.
Domest Anim Endocrinol · 2017
Last updated 2026-05-28In cattle, a modified version of oxyntomodulin called [Gly, Glu]-OXM lowered blood sugar and increased insulin, while a glucagon-based compound called [Gly, Glu]-glucandin also raised insulin but required a higher dose of 3.2 micrograms per kilogram to affect blood sugar. Another compound, [Gly, Glu]-glucagon, increased insulin but did not change blood sugar levels. The effects of [Gly, Glu]-OXM were nearly as strong as a diabetes drug called Ex-4 in lowering blood sugar.
AI summary of the abstract below.
| Journal | Domest Anim Endocrinol, 2017 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.12 |
| NIH percentile | 9 |
| Molecules | — |
Abstract
The present study was undertaken with the aim of examining whether and how exendin-4 (1-3) fragment, ie, Ex-4 (1-3) fragment, contributes to the regulation of glucose. An analog of oxyntomodulin (OXM) ([Gly, Glu]-OXM), a glucagon analog ([Gly, Glu]-glucagon), and two derivatives of Ex-4 (glucandin and [Gly, Glu]-glucandin) were synthesized by substituting with Gly, Glu at the N-terminuses of OXM and glucagon and/or by attaching Ex-4 (30-39) amide at the C-terminus of glucagon. Effects of these peptides on plasma insulin and glucose concentrations were investigated in cattle by conducting 3 in vivo experiments. In all 3 experiments, 0.1% BSA saline was injected as a control. In experiment 1, glucandin (amino acid sequence was glucagon [1-29]-Ex-4 [30-39] amide) and [Gly, Glu]-glucandin were injected at the dose rates of 5 μg/kg BW in 4-mo-old Holstein steers. Results showed that glucoregulatory effects of glucandin were similar to those of glucagon. [Gly, Glu]-glucandin stimulated insulin secretion at 2 to 10 min and lowered glucose concentrations at 15 to 75 min. Experiment 2 was carried out to better understand the glucose-lowering potency of [Gly, Glu]-glucandin, in comparison with Ex-4 and glucagon-like peptide-1 (GLP-1), using 4.5-mo-old Holstein steers. [Gly, Glu]-glucandin was injected at dose rates of 0.3 μg/kg BW, 1.0 μg/kg BW, 3.2 μg/kg BW, and 6.4 μg/kg BW. Ex-4 and GLP-1 were injected at dose rates of 0.3 μg/kg BW. Results showed that the insulinotropic and glucose-lowering effects of [Gly, Glu]-glucandin were not as potent as for Ex-4 and GLP-1, and the minimum effective dose of [Gly, Glu]-glucandin to regulate plasma glucose concentrations was 3.2 μg/kg BW. In experiment 3, [Gly, Glu]-OXM and [Gly, Glu]-glucagon were injected at dose rates of 5 μg/kg BW in 5-mo-old Holstein steers. Both [Gly, Glu]-OXM and [Gly, Glu]-glucagon increased insulin concentration. [Gly, Glu]-OXM potently lowered plasma glucose, but [Gly, Glu]-glucagon did not change it. In summary, our findings clearly demonstrate that Ex-4 (1-3) fragment contributes to the regulation of glucose. [Gly, Glu]-OXM and [Gly, Glu]-glucandin are insulinotropic and glucose-lowering peptides. It was of interest that the substitution of the first 3 amino acids of OXM with Ex-4 (1-3) could reverse the upregulation of glucose by OXM into downregulation of glucose. In lowering glycemia, [Gly, Glu]-OXM seemed almost as effective as Ex-4, and [Gly, Glu]-glucandin was less profound than Ex-4. These findings contributed new insights into the hormonal regulation of glucose in ruminants. The action of [Gly, Glu]-OXM and [Gly, Glu]-glucandin might provide an advantage in glycemic control of insulin resistance in cattle and humans.
Verbatim abstract via PubMed 27888738 ↗